# Tizona Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tizona-therapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.tizonatx.com
- Total disclosed funding: $70M
- Latest round: Series B (Feb 22, 2016)
- Investors on record: 7

## About

Tizona Therapeutics, Inc. is a biopharmaceutical company dedicated to developing advanced immunotherapies aimed at enhancing cancer treatment outcomes for patients, leveraging innovative approaches to harness the body's immune response.Founded in 2014 and headquartered in San Francisco, US, Tizona Therapeutics is focused on developing immunotherapy treatments. In July 2020, Gilead Sciences, Inc. acquired a 49.9 percent stake in the company for USD 300 mn, with an option to acquire the remaining shares for an additional USD 1.25 bn. The firm has completed 3 deals since its inception, with the most recent deal occurring on July 21, 2020. The CEO of the company is Christine Obrien.Tizona Therapeutics develops innovative immunotherapies aimed at improving cancer treatment outcomes. Their lead product, TTX-080, is designed to enhance the effectiveness of treatments like the EGFR inhibitor Cetuximab and chemotherapy for advanced colorectal cancer. The company collaborates with healthcare providers and research institutions in North America and Europe to facilitate access to its therapies, serving a diverse client base, including oncologists and cancer treatment centers, specifically for patients with colorectal cancer and head and neck squamous cell carcinoma.Tizona Therapeutics primarily generates revenue through partnerships with healthcare institutions and pharmaceutical companies for clinical trial collaborations. These partnerships may involve funding trials in exchange for access to generated data. The company's revenue model includes milestone payments based on achieving clinical endpoints and royalties on future sales upon regulatory approval. Revenue from these collaborations is influenced by negotiations with healthcare providers and the competitive oncology market.Tizona Therapeutics plans to utilize recent funding from Gilead Sciences, Inc. to advance its immunotherapy product development and potentially expand into new geographic markets. The focus is on launching new products, including TTX-080, and enhancing their clinical trials. The recent investment of USD 300 mn will support these initiatives while also aiming for strategic collaborations in North America and Europe, which are targeted for expansion in the coming years.

## Funding rounds

- Series B, Feb 22, 2016, $43M — Abingworth, InterWest Partners, Canaan Partners, Astellas Venture Management, Amgen Ventures, MPM BioImpact, Lightstone Ventures
- Series A, Jan 10, 2016, $27M — InterWest Partners, Astellas Venture Management, Amgen Ventures, MPM BioImpact

## Investors

- InterWest Partners (https://capitalatlas.ai/funds/interwest-partners) — Series A, Series B
- Astellas Venture Management (https://capitalatlas.ai/funds/astellas-venture-management) — Series A, Series B
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series A, Series B
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B
- Abingworth (https://capitalatlas.ai/funds/abingworth) — Series B
- Canaan Partners (https://capitalatlas.ai/funds/canaan-partners) — Series B
- Lightstone Ventures (https://capitalatlas.ai/funds/lightstone-ventures) — Series B